N-Acetyl Cysteine (NAC) for COPD

N-acetylcysteine has one of the most specific evidence profiles in respiratory medicine: at a high enough dose, it reduces the number of exacerbations in people with COPD and chronic bronchitis. What it does not do is improve lung function or slow the decline in FEV1. Dose is the whole story. Trials using 600 mg daily produced weak or negative results, while trials using 1200 mg daily, notably the PANTHEON and HIACE studies, showed meaningful reductions in exacerbation frequency, particularly in people with a chronic productive cough and frequent flares. That makes NAC an adjunct with a defined role: it sits on top of inhaled therapy for a specific phenotype, and it is not a substitute for bronchodilators, inhaled steroids, pulmonary rehabilitation or smoking cessation.

The Cochrane mucolytics review is worth reading alongside the positive trials. It found a small reduction in exacerbations and days of disability across mucolytic agents overall, but noted that older trials predate modern inhaled therapy, so the added benefit on top of current treatment is likely smaller than the raw numbers suggest. The practical framing: worth discussing with your respiratory team if you have frequent exacerbations and sputum, less compelling if your COPD is stable and dry.

NAC works on two fronts in the airway. Its free thiol group breaks the disulphide bridges that cross-link mucin polymers, which lowers sputum viscosity and makes secretions easier to clear. That is the classic mucolytic action, and it is why the effect concentrates in people who produce sputum. The second mechanism is antioxidant. NAC is a precursor to cysteine, the rate-limiting substrate for glutathione synthesis, and glutathione is the lung's principal defence against the oxidative burden of cigarette smoke and neutrophilic inflammation. Restoring airway glutathione dampens NF-kB-driven inflammatory signalling and reduces bacterial biofilm adherence to epithelium, which plausibly explains why exacerbations, rather than spirometry, are the outcome that moves.

For COPD, 1200 mg daily in two divided doses is the dose supported by the trials that worked. The 600 mg daily regimen used in earlier studies, including BRONCUS, did not reduce exacerbations, so under-dosing is the most common reason a trial of NAC fails. Treat it as a long-term, preventive therapy rather than a rescue medicine: benefit in trials emerged over six to twelve months of continuous use. Effervescent tablets dissolved in water are better tolerated than capsules for some people, and taking it with food reduces nausea.

The dose-response pattern across trials is unusually clear. A 2014 randomised trial of 600 mg twice daily reported fewer exacerbations over a year, and a 2015 meta-analysis concluded that high-dose NAC reduces exacerbation frequency in chronic bronchitis and COPD while low-dose regimens do not. Earlier work using 600 mg daily, including the 2005 BRONCUS trial, found no effect on exacerbation rate or FEV1 decline. The 2019 Cochrane review of mucolytics places this in context: a modest reduction in exacerbations and disability days across the class, with the caveat that much of the evidence predates current inhaled therapy and effect sizes are small. Lung function remains unchanged in every analysis.

Oral NAC is well tolerated at 1200 mg daily. The common effects are nausea, vomiting, diarrhoea and an unpleasant sulphurous taste and smell, most of which improve when taken with food or as a dissolved effervescent tablet. Two cautions are worth naming. Rare bronchospasm has been reported, mainly with nebulised NAC in people with asthma, so anyone with asthma-COPD overlap should start under medical advice. And because NAC has mild antiplatelet activity and may modestly enhance anticoagulant effect, it should be reviewed before surgery and in anyone on warfarin. Isolated reports link NAC to worsened heartburn and, rarely, hypersensitivity reactions.

NAC has few serious drug interactions, but its thiol chemistry means it can react with some drugs directly and can add to bleeding risk. The important ones concern nitrates, anticoagulants and antibiotics given at the same time.